Classification and Prognostication of B‐Cell and T‐Cell Multicentric Lymphoma in Dogs Using Serum MicroRNAs
Veterinary and Comparative Oncology · 2025
DOI: 10.1111/vco.13057 ↗Kurz gefasst
Fachartikel in der Zeitschrift Veterinary and Comparative Oncology, 2025. Verfasst von Latasha Ludwig und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathobiology, University of Guelph, Guelph, Ontario, Canada. Hauptthemen laut MEDLINE: Dog Diseases, MicroRNAs, Lymphoma, B-Cell, Lymphoma, T-Cell. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Ontario Veterinary College, University of Guelph, OVC Pet Trust, Natural Sciences and Engineering Research Council of Canada.
Abstract (Originalsprache)
Canine multicentric lymphoma is a common malignancy in dogs. It often responds well to initial chemotherapy but frequently relapses and has a poor response to subsequent treatment. B‐cell (BCL) and T‐cell (TCL) lymphomas differ in both their prognoses and chemotherapeutic treatment protocols. Currently, immunophenotyping can be costly and can only be performed on specific high‐quality samples. MicroRNAs (miRNAs) are small molecules present in blood and tissues and are dysregulated in both human and canine lymphoma. We investigated 59 miRNAs by RT‐qPCR to establish a serum miRNA profile in dogs with B‐cell and T‐cell multicentric lymphoma. Multiple miRNA pruned decision tree models were used to classify BCL and TCL cases from each other and controls, and to predict prognosis in BCL cases receiving standard CHOP chemotherapy. Six individual miRNAs were differentially expressed in serum between BCL and controls, and three were differentially expressed between BCL and TCL. A three‐miRNA model (miR‐155‐5p, miR‐1 and miR‐181b) could differentiate between BCL, TCL and control samples with an accuracy of 83.02%. A three‐miRNA model (miR‐125b‐5p, miR‐350 and let‐7b‐5p) in BCL samples separated the cases into four groups with hazard ratios ranging from 0.44 to 3.5 for overall survival. This study established a serum miRNA profile for both BCL and TCL and demonstrated the utility of multiple serum miRNA models to assist in the diagnosis of lymphoma and BCL prognostication.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathobiology, University of Guelph, Guelph, Ontario, Canada.
- Department of Population Medicine and Diagnostic Sciences, Cornell University, Ithaca, New York, United States.
- Department of Biomedical Sciences, University of Guelph, Guelph, Ontario, Canada.
- Department of Mathematics and Statistics, University of Guelph, Guelph, Ontario, Canada.
ORCID-Profile: Latasha Ludwig, Geoffrey A Wood
Förderung
- Ontario Veterinary College, University of Guelph
- OVC Pet Trust
- Natural Sciences and Engineering Research Council of Canada
Zitieren
APA
Ludwig, L., Treleaven, H., Moorehead, R., Foster, R. A., Wood, R. D., Ali, R. A., & Wood, G. A. (2025). Classification and Prognostication of B‐Cell and T‐Cell Multicentric Lymphoma in Dogs Using Serum MicroRNAs. Veterinary and Comparative Oncology. https://doi.org/10.1111/vco.13057
Vancouver
Ludwig L, Treleaven H, Moorehead R, Foster RA, Wood RD, Ali RA, et al. Classification and Prognostication of B‐Cell and T‐Cell Multicentric Lymphoma in Dogs Using Serum MicroRNAs. Veterinary and Comparative Oncology. 2025. doi:10.1111/vco.13057
BibTeX
@article{Ludwig2025,
author = {Ludwig, Latasha and Treleaven, Heather and Moorehead, Roger and Foster, Robert A and Wood, R Darren and Ali, R Ayesha and Wood, Geoffrey A},
title = {Classification and Prognostication of B‐Cell and T‐Cell Multicentric Lymphoma in Dogs Using Serum MicroRNAs},
journal = {Veterinary and Comparative Oncology},
year = {2025},
doi = {10.1111/vco.13057}
}
EUVIMED